BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12771997)

  • 1. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.
    Galmarini CM; Kamath K; Vanier-Viornery A; Hervieu V; Peiller E; Falette N; Puisieux A; Ann Jordan M; Dumontet C
    Br J Cancer; 2003 Jun; 88(11):1793-9. PubMed ID: 12771997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.
    Galmarini CM; Falette N; Tabone E; Levrat C; Britten R; Voorzanger-Rousselot N; Roesch-Gateau O; Vanier-Viornery A; Puisieux A; Dumontet C
    Br J Cancer; 2001 Sep; 85(6):902-8. PubMed ID: 11556844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.
    Rathinasamy K; Jindal B; Asthana J; Singh P; Balaji PV; Panda D
    BMC Cancer; 2010 May; 10():213. PubMed ID: 20482847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
    Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
    Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
    Mirza A; McGuirk M; Hockenberry TN; Wu Q; Ashar H; Black S; Wen SF; Wang L; Kirschmeier P; Bishop WR; Nielsen LL; Pickett CB; Liu S
    Oncogene; 2002 Apr; 21(17):2613-22. PubMed ID: 11965534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
    Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
    Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
    Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C
    Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line.
    Chang E; Donahue J; Smith A; Hornick J; Rao JN; Wang JY; Battafarano RJ
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):225-32. PubMed ID: 20236666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines.
    He L; Yang CP; Horwitz SB
    Mol Cancer Ther; 2001 Nov; 1(1):3-10. PubMed ID: 12467233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer.
    Végran F; Boidot R; Oudin C; Defrain C; Rebucci M; Lizard-Nacol S
    Oncogene; 2007 Jan; 26(2):290-7. PubMed ID: 16847456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
    Rai A; Surolia A; Panda D
    PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.
    Cheung CH; Chen HH; Kuo CC; Chang CY; Coumar MS; Hsieh HP; Chang JY
    Mol Cancer; 2009 Jul; 8():43. PubMed ID: 19575780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
    BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53.
    Hoffman WH; Biade S; Zilfou JT; Chen J; Murphy M
    J Biol Chem; 2002 Feb; 277(5):3247-57. PubMed ID: 11714700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.
    Don S; Verrills NM; Liaw TY; Liu ML; Norris MD; Haber M; Kavallaris M
    Mol Cancer Ther; 2004 Sep; 3(9):1137-46. PubMed ID: 15367708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.
    Hage-Sleiman R; Herveau S; Matera EL; Laurier JF; Dumontet C
    BMC Cancer; 2010 Apr; 10():135. PubMed ID: 20384997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells.
    Beghin A; Honore S; Messana C; Matera EL; Aim J; Burlinchon S; Braguer D; Dumontet C
    Exp Cell Res; 2007 Feb; 313(3):473-85. PubMed ID: 17188265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells.
    Lilling G; Nordenberg J; Rotter V; Goldfinger N; Peller S; Sidi Y
    Cancer Invest; 2002; 20(4):509-17. PubMed ID: 12094546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.